Vistin Pharma is one of the leading global Metformin producers. Metformin is used as standard first line treatment for Type 2 diabetes.

A worker at our facilities.

PRODUCTS

Metformin is the standard first line treatment for Type 2 Diabetes, a disease that is expected to grow by 50% until 2045 worldwide and affect more than 700 million people. The global market for Metformin is expected to grow with a CAGR of 4-6% on an annual basis. Vistin Pharma is strategically well positioned to take part of this growth.
  • Unique Offering

  • High delivery performance (>98%), on time in full
  • Flexible customer solutions and excellent customer service
  • Competitive pricing due to economy of scale
  • Strong focus on Environment, Social and Health (ESG)
  • Customized Particle Size Distribution
  • All shipments according to GDP (Good Distribution Practice)
  • API with no detectable content of nitrosamine
  • Low levels of residual DMA, impurity
  • Best free-flowing API on the market

Our Metformin products

Metformin HCl

Metformin DC

Premix

Our Metformin HCl is synthesised and processed to supply the market with the purest and best free-flowing quality. Vistin Pharma API has no detectable levels of Nitrosamines, and very low levels of residual DMA (Impurity F)

Regulatory status:

Certificate of Suitability to the European Pharmacopoeia (CEP) and European DMF
Letter of Authorisation to the US DMF available on request
Manufactured according to current Good Manufacturing Practice (cGMP)
Inspected by the US Food and Drug Administration (FDA), Brazilian Health Authorities (ANVISA ), Korean Health Authorities (KFDA), Japanese Health Authority (PMDA) and the Norwegian Medicines Agency
Batch size: 3100 kg
Compliance: Ph.Eur, JP and USP
Manufacturing and release: Fikkjebakke, Kragerø, Norway
Packaging: 25 kg net, packed in sealed double polyethylene bags in cardboard carton.
Re-test period 5 years when stored in sealed double polyethylene bags in cardboard carton.
Metformin direct compressible (DC) grade 92.6% is with magnesium stearate (lubricant), and thus direct compressible material intended for plain Metformin immediate release tablets. Metformin DC 95% grade available on request.

Regulatory status:

Letter of Authorisation to the US DMF
available on request
Manufactured according to
current Good Manufacturing Practice (cGMP)
Inspected by the US Food and Drug Administration (FDA) and the Norwegian Medicines Agency
Batch size: 800 kg
Compliance: : Ph.Eur and USP
Manufacturing and release: Fikkjebakke, Kragerø, Norway
Packaging: 25 kg net, packed in sealed double polyethylene bags in fiber drums. 400 and 800kg Big Bag packaging on request.
Shelf-life: 2 years when stored in sealed  double polyethylene bags in fiber drums
Metformin Premixed with lubricant Magnesium Stearate (MgSt) for use in plain Metformin immediate release tablets. Available on request
Packaging: 25 kg net, packed in sealed double polyethylene bags in cardboard carton or various sized Big Bag.
Manufacturing & release: Fikkjebakke, Kragerø, Norway
Our Metformin HCl is synthesised and processed to supply the market with the purest and best free-flowing quality. Vistin Pharma API has no detectable levels of Nitrosamines, and very low levels of residual DMA (Impurity F)

Regulatory status:

Certificate of Suitability to the European Pharmacopoeia (CEP) and European DMF
Letter of Authorisation to the US DMF available on request
Manufactured according to current Good Manufacturing Practice (cGMP)
Inspected by the US Food and Drug Administration (FDA), Brazilian Health Authorities (ANVISA ), Korean Health Authorities (KFDA), Japanese Health Authority (PMDA) and the Norwegian Medicines Agency
Batch size: 3100 kg
Compliance: Ph.Eur., BP, JP and USP
Manufacturing and release: Kragerø, Norway
Packing: 25 kg net, packed in sealed double polyethylene bags in cardboard carton. 400 and 800kg Big Bag packaging available on request
Re-test period 2 years when stored in sealed
double polyethylene bags in fiber
drums/cartons
Metformin direct compressible (DC) grade 92.6% is with magnesium stearate (lubricant), and thus direct compressible material intended for plain Metformin immediate release tablets. Metformin DC 95% grade available on request.

Regulatory status:

Letter of Authorisation to the US DMF
available on request
Manufactured according to
current Good Manufacturing Practice (cGMP)
Inspected by the US Food and Drug Administration (FDA) and the Norwegian Medicines Agency
Batch size: 800 kg
Compliance: USP for the API
Manufacturing and release: Kragerø, Norway
Packaging: 25 kg net, packed in sealed double polyethylene bags in fiber drums/cartons. 400 and 800kg Big Bag packaging on request.
Shelf-life: 2 years when stored in sealed
double polyethylene bags in fiber
drums/cartons
Metformin + MgSt, can be delivered on-request

EXPANSION 
PROJECT

EXPANSION PROJECT

Double capacity
Double care

By 2020 Vistin Pharma was not able to meet the demand from existing and new customers. A strong and stable growth in the metformin market and a strong demand for Vistin Pharma’s premium products lead to a decision in April 2020 to invest MNOK 100 to increase the capacity at Fikkjebakke. The capacity will increase from 3800MT and up to 7000MT by 2023.

In Vistin Pharma we have a continuous focus on developing our manufacturing abilities.

In 2018 we ran a CREEP project that improved operational efficiency and processes followed up by a 100 MNOK investment decision to increase capacity and develop our facilities further in 2020. With continued focus on the implementation of LEAN philosophy and Operational Excellence performance to establish a «right first time» culture and “world class” work processes in the organization, we are now running one of the most advanced productions of metformin in the world.
  • Examples of technology development in the interface between production and sustainable operations

  • closed cooling water concept (reduce consumption of water and utilize energy in used cooling water)
  • degradation of Metformin in water (develop technology to degrade metformin efficiently)
  • distillation waste (separate components in distillation waste)
  • work with process system to reduce VOC (emissions to air).
Together with our ambitions to be a front runner on sustainability we have further strengthened our competitive advantages compared to competition.

Projects such as our closed cooling water concept (reduce consumption of water and utilize energy in used cooling water), degradation of Metformin in water (develop technology to degrade metformin efficiently), distillation waste from SYA2 (separate components in distillation waste), and work with process system to reduce VOC (emissions to air) so that new requirements from authorities are met are examples of technology development in the interface between production and sustainable operations.

TECHNOLOGY

Sustainability

Balance by Vistin, our sustainability concept

In 2022 we initiated a new concept and program called Balance by Vistin to focus further on improvements internally, but also to establish the company as a front-runner within sustainable production and act as an inspiration for people and companies. Read more about our ESG initiatives at Balance by Vistin.
MORE SUSTAINABILITY

Sustainability

Quality

Vistin Pharma is a Norwegian manufacturer of medicinal products of high quality. The company sells pharmaceutical intermediates and APIs to global pharmaceutical companies. Our employees are well skilled and we are manufacturing products of premium quality. We are approved by medicinal authorities in many countries and are regularly inspected by authorities in Norway and the US (FDA).

Licenses to operate

The Company has been granted
the following authorisation:

Manufacturers Authorisation for medicinal products including Investigational Medicinal Products, limited to non-sterile products and manufacture of API and Quality control testing (chemical/physical), wholesale, importation - valid until 01 October 2022 for the Fikkjebakke site.
The licenses issued by the Norwegian Medicines Agency (NoMA, Statens Legemiddelverk) are granted according to the Norwegian Act of 4 December 1992 on Medicinal Products and ”Guidelines to Good Manufacturing Practice” issued by the European Commision, cf. Directives 2003/94/EC and 91/412/EC”. All licenses are available at Eudra GMP.

Authority GMP
inspections

List of authority GMP inspections the last 5 years:

  • NoMA GMP audit 15-18 March 2022
  • FDA (USA) GMP audit 20-24 May 2019

In addition, the following authorities have inspected Vistin Pharma:

  • KFDA (South Korea) audit 6 -7 February 2012
  • ANVISA (Brazilian) GMP audit 2 – 6 May 2011
Copies of GMP certificate and Manufacturing Licenses for the Fikkjebakke site are available at Eudra GMDP - Public Layout (europa.eu)

The quality
management system

The quality system in Vistin is based
on the following guidelines:

QA is responsible for in-house GMP training and the administration of the Standard Operation Procedures (SOPs).

QA is responsible for planning and performing internal and external audits and issuing audit reports. The purpose of the audits is to make a survey of how the activities are carried out according to GMP, internal regulations, and customer/authority requirements. The audits secure that any divergence from the regulations will lead to implementation of necessary improvements.
The Qualified Persons (QPs) must be approved by NoMA and have the final responsibility for approval/release or rejection of API and Metformin granulate. Batch records are reviewed and controlled by the Quality Unit before release of each batch.

Vistin Pharma AS currently has 5 Qualified Persons (incl. trainees).

Detailed description of individual and department responsibilities are maintained in written job descriptions and responsibility matrixes.

Quality Management

Vistin Pharma AS has a separate Quality Unit (Q), divided in QA Assurance (QA) and Quality Control (QC) functions professionally independent of production, reporting directly to the Chief Executive Officer (CEO) as well as Regulatory Affairs (RA). The responsible person for the Quality activities is the Vice President Quality and Regulatory Affairs. The main responsibility of QA is to establish and maintain all systems necessary according to GMP and other relevant quality standards (GDP). An important instrument in monitoring quality is the Quality Management Review (QMR).